The Pharma Data

SEPTEMBER 6, 2021

Over 70% of breast cancer cases are hormone receptor (HR)-positive, and there is a need for more effective and tolerable treatments, since up to 30% of patients develop resistance to standard of care treatments and in the adjuvant setting half of patients stop treatment due to the toll of side effects. Lung Cancer Highlights. Real world data.

Genomics 52

Genomics Genome HR Hormones 52

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 101

FDA Approval Drugs Sales Development 101

Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

The Pharma Data

DECEMBER 21, 2020

Adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% in the primary endpoint of DFS in patients with Stage II and IIIA disease (hazard ratio [HR] 0.17; 95% confidence interval [CI] 0.12-0.23; 0.23; p<0.0001). 0.27; p<0.0001).

Trials 52

Trials Medicine HR Development 52

Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Drugs 110

Drugs Licensing Licensing Production 110

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

SEPTEMBER 2, 2021

Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies. CAPItello-292: a phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2-advanced breast cancer. DNA damage response. Abstract #1165P. Hamilton, E.

Trials 52

Trials Medicine Antibody Clinical Trials 52

Pfizer

DECEMBER 20, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets).

Drugs 69

Drugs Licensing Licensing Containment 69

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Marketing 75

Marketing Production Drugs Licensing 75

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. 5) Lynparza (Olaparib) Lynparza is a PARP inhibitor , meaning it inhibits poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

NOVEMBER 23, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

Pharmaceutical Technology

MAY 9, 2023

During his time at General Electric Corporate, he managed the transition of more than 120 HR processes from 12 different business units into a single shared services centre. Jamaels brings expertise from diverse environments to the challenge of change management at Cerba Research.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Big Data 130

XTalks

FEBRUARY 27, 2025

SERENA-6 is unique as the first global, double-blind study to use circulating tumor DNA (ctDNA) monitoring a blood-based approach to detect early signs of endocrine resistance. By tracking small fragments of tumor DNA in the bloodstream, researchers identified the emergence of ESR1 mutations before clinical progression appeared.

Trials 59

Trials HR Clinical Trials Clinical Trials 59